28 Oct

Biosimilars IP playbook is being re-written by the rise of interchangeables

FDA’s approval of the first interchangeable monoclonal antibody has highlighted the complexities of regulatory exclusivity, while the introduction of more such drugs will alter impact IP strategies in years to come.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth